Patterns of Failure in Endometrial Carcinoma Stage IB Grade 3 and IC Patients Treated with Postoperative Vaginal Vault Brachytherapy

Chadha, Manjeet; Nanavati, Parashar J.; Liu, P.; Fanning, James; Jacobs, Andrew

doi:10.1006/gyno.1999.5526

Cited by 122 publications

(39 citation statements)

References 19 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…This finding prompted the increased use of adjuvant vaginal brachytherapy alone for patients with tumors that are histologically confined to the uterus, despite the existence of other intrauterine risk features. 31,[47][48][49] The GOG randomized trial has also been criticized for including patients with a broad range of relapse risk, including many who probably have excellent prognoses with surgery alone, hence diluting the possibility of detecting a benefit to adjuvant therapy.…”

Section: Completely Surgically Staged Patientsmentioning

confidence: 99%

Uterine Neoplasms

Greer¹,

Wj²,

Abu‐Rustum³

et al. 2009

J Natl Compr Canc Netw

View full text Add to dashboard Cite

Section: Completely Surgically Staged Patientsmentioning

confidence: 99%

Uterine Neoplasms

Greer¹,

Wj²,

Abu‐Rustum³

et al. 2009

J Natl Compr Canc Netw

View full text Add to dashboard Cite

“…Adjuvant radiation therapy to the pelvis has been used to treat residual disease and reduce the risk of pelvic recurrence in such patients (5)(6)(7)(8)(9). Unfortunately, many women with high-risk pathological features ultimately develop extrapelvic metastases, despite receiving adjuvant radiation therapy (10 -15).…”

Section: Introductionmentioning

confidence: 99%

Prognostic Significance of E-Cadherin Protein Expression in Pathological Stage I-III Endometrial Cancer

Mell¹,

Meyer²,

Tretiakova³

et al. 2004

Clinical Cancer Research

View full text Add to dashboard Cite

Purpose: Decreased expression of E-cadherin in endometrial cancer cells is associated with adverse prognostic features. This study aimed to evaluate the prognostic significance of decreased E-cadherin expression in patients with endometrial cancer.Experimental Design: Between 1992 and 1999, 102 endometrial cancer patients with stage I-III disease underwent primary surgery at the University of Chicago. Representative tissue specimens were immunostained with a monoclonal antibody to E-cadherin. A semiquantitative evaluation scale was developed based on the percentage of endometrial cancer cells with membranous E-cadherin staining. Tissue sections were scored as "3" if >75%, "2" if 25-75%, "1" if 5-25%, and "0" if <5% of cells stained. E-Cadherin staining was correlated with overall survival (OS), cause-specific survival (CSS), progression-free survival (PFS), and extrapelvic progression. Multivariate Cox proportional hazards modeling was used to estimate hazard ratios, controlling for clinicopathological characteristics and adjuvant treatment. Median follow-up for the study group was 58.5 months.Results: E-Cadherin staining was scored as 0, 1, 2, and 3 in 29.4%, 18.6%, 26.5%, 25.5% of cases, respectively. E-Cadherin expression was positively correlated with myometrial invasion (Kendall : 0.30, P < 0.01), and negatively correlated with grade (Kendall : ؊0.13, P ‫؍‬ 0.15) and papillary serous or clear cell histology (Kendall : ؊0.14, P ‫؍‬ 0.12). Five-year actuarial OS, CSS, PFS, and extrapelvic recurrence rates for negative (score ‫؍‬ 0), heterogeneous Conclusions: Decreased E-cadherin expression is an independent prognostic factor for disease progression and mortality in pathological stage I-III endometrial cancer. Evaluation of E-cadherin expression may aid in the selection of patients for more aggressive adjuvant therapy.

show abstract

“…Recent data suggest that vaginal brachytherapy may be used instead of external beam RT to obtain equally high local control rates with less side effects and, consequently, to obtain optimal disease-free and overall survival rates as well as best quality of life [7][8][9]. This is the rationale of the currently ongoing PORTEC-2 trial, randomizing between postoperative pelvic RT and vaginal brachytherapy.…”

Section: Randomized Trials On Radiotherapy In Intermediate Risk Endommentioning

confidence: 96%

The role of radiotherapy in the treatment of endometrial carcinoma

Creutzberg

2005

International Congress Series

View full text Add to dashboard Cite

Patterns of Failure in Endometrial Carcinoma Stage IB Grade 3 and IC Patients Treated with Postoperative Vaginal Vault Brachytherapy

Cited by 122 publications

References 19 publications

Uterine Neoplasms

Uterine Neoplasms

Prognostic Significance of E-Cadherin Protein Expression in Pathological Stage I-III Endometrial Cancer

The role of radiotherapy in the treatment of endometrial carcinoma

Contact Info

Product

Resources

About